Andrew Serafin serves as the Executive Vice President and Chief Strategy Officer at Harmony Biosciences Holdings Inc., a pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases. In his role, Serafin is responsible for overseeing the company's strategic planning and development, ensuring that Harmony Biosciences remains at the forefront of innovation in the treatment of rare neurological disorders. His leadership has been instrumental in guiding the company through its growth and expansion, as well as in the successful launch and commercialization of its flagship product, Wakix (pitolisant), the first and only treatment approved in the U.S. for excessive daytime sleepiness in adult patients with narcolepsy. Prior to joining Harmony Biosciences, Serafin held several high-level positions in the pharmaceutical industry, where he gained extensive experience in strategic planning, business development, and product commercialization. He previously served as the Senior Vice President of Strategy and Business Development at Teva Pharmaceuticals, one of the world's leading generic drug manufacturers. During his tenure at Teva, Serafin played a key role in the company's strategic initiatives, including the successful acquisition and integration of several businesses that strengthened Teva's position in the global market. Before Teva, he held various roles at Novartis and Bristol-Myers Squibb, where he contributed to the development and launch of several successful products. Serafin's professional achievements have been recognized throughout his career, and his strategic vision has been a driving force behind Harmony Biosciences' success. With his deep understanding of the pharmaceutical industry and his commitment to improving the lives of patients with rare neurological diseases, Serafin continues to lead the company's efforts to develop and deliver innovative treatments that address unmet medical needs.